Retatrutide Lyophilized Peptide Powder

Retatrutide, also identified in published research as LY3437943, is a synthetic, acylated single peptide developed as a triple agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR).

This lyophilized material is supplied solely for qualified laboratory research involving multi-receptor pharmacology, peptide–receptor interactions, and intracellular signaling. Potential research applications include analytical characterization, receptor-activation studies, comparative agonist profiling, and the investigation of coordinated GIPR, GLP-1R, and GCGR signaling in appropriate biochemical or cellular models.

Retatrutide’s activity across three related class B G protein-coupled receptors makes it a relevant research compound for examining receptor selectivity, downstream signaling pathways, endocrine communication, and the integration of incretin- and glucagon-associated signaling under controlled experimental conditions.

Retatrutide remains an investigational compound. No FDA-approved drug product currently contains retatrutide. This independently supplied research material is not an FDA-approved drug product and is not intended for compounding or administration.

For Research Use Only. Not for human or veterinary use. Not for diagnostic, therapeutic, clinical, compounding, or household applications.